Injectable Nanomaterial Shows Promise in Protecting Brain Tissue After Stroke
When someone suffers from a stroke, the standard treatment to restore blood flow to the brain can save their life but also cause additional damage. A new injectable nanomaterial called IKVAV-PA offers hope in protecting against this damage, as developed by researchers at Northwestern University in the US. Previously shown to repair tissue in a mouse model of spinal cord injuries, this regenerative material was tested on a mouse model of acute ischemic stroke, the most common type.
At the heart of this treatment are supramolecular therapeutic peptides (STPs), also known as ‘dancing molecules’ due to their dynamic biological interactions. This feature makes them more versatile when interacting with target cells, providing a more adaptable approach to treatment.
One key innovation in this study was the use of systemic delivery, where the molecules are injected into the bloodstream. This method is fast, simple to administer, and less invasive compared to direct brain delivery. According to materials scientist Samuel Stupp, this delivery mechanism could also be beneficial in treating traumatic brain injuries and neurodegenerative diseases.
In the mouse trials, the injected biomaterial successfully reached the brain through the bloodstream with minimal side effects. Compared to untreated mice, those treated with IKVAV-PA showed less brain tissue damage, reduced inflammation, and fewer harmful immune responses post-stroke.
The main role of IKVAV-PA is to stimulate nerve cells to repair themselves after injury while keeping inflammation in check. This is crucial as inflammation can escalate due to the initial blood flow blockage.
According to Stupp, the molecules carry anti-inflammatory activity to counteract the harmful effects of released molecules post-clot removal, aiding in neural network repair.
Stroke treatment requires a delicate balance post-clot removal to prevent collateral damage and long-term disability. IKVAV-PA could potentially serve as a secondary treatment alongside reperfusion, but human trials and long-term safety assessments are necessary.
With millions affected by strokes annually and a significant number of deaths and disabilities resulting from them, IKVAV-PA could make a significant impact. Neuroscientist Ayush Batra emphasizes the potential of this therapy in reducing disability, restoring function, and minimizing injury post-stroke.
The research findings have been published in Neurotherapeutics.
